EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine

Dilara Onan iD, Fatemeh Farham, Paolo Martelletti iD

Toxins · 07.07.2024 · 16 (7) · 309

DOI: 10.3390/toxins16070309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxins, online erschienen am 07.07.2024. Verfasst von Dilara Onan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiotherapy and Rehabilitation, Faculty of Heath Sciences, Yozgat Bozok University, Yozgat 66000, Turkey. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OnabotulinumtoxinA (BT-A) is used in different medical fields for its beneficial effects. BT-A, a toxin originally produced by the bacterium Clostridium botulinum, is widely known for its ability to temporarily paralyze muscles by blocking the release of acetylcholine, a neurotransmitter involved in muscle contraction. The literature continually reports new hypotheses regarding potential applications that do not consider blockade of acetylcholine release at the neuromuscular junction as a common pathway. In this opinion article, it is our aim to investigate the different pathway targets of BT-A in different medical applications. First of all, the acetylcholine effect of BT-A is used to reduce wrinkles for cosmetic purposes, in the treatment of urological problems, excessive sweating, temporomandibular joint disorders, obesity, migraine, spasticity in neurological diseases, and in various cases of muscle overactivity such as cervical dystonia, blepharospasm, and essential head tremor. In another potential pathway, glutamate A, CGRP, and substance P are targeted for pain inhibition with BT-A application in conditions such as migraine, trigeminal neuralgia, neuropathic pain, and myofascial pain syndrome. On the other hand, as a mechanism different from acetylcholine and pain mediators, BT-A is used in the treatment of hair loss by increasing oxygenation and targeting transforming growth factor-beta 1 cells. In addition, the effect of BT-A on the apoptosis of cancer cells is also known and is being developed. The benefits of BT-A applied in different doses to different regions for different medical purposes are shown in literature studies, and it is also emphasized in those studies that repeating the applications increases the benefits in the long term. The use of BT-A continues to expand as researchers discover new potential therapeutic uses for this versatile toxin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AHumansAnimalsAcetylcholine Release InhibitorsPainAcetylcholineNeuromuscular Agents

Stichwörter der Autor:innen

CGRPOnabotulinumtoxinAchronic migraineexcessive sweatinghair lossspasticitytrigeminal neuralgiawrinkle

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin AAcetylcholine Release InhibitorsAcetylcholineNeuromuscular Agents

Autor:innen und Institutionen

  • Department of Physiotherapy and Rehabilitation, Faculty of Heath Sciences, Yozgat Bozok University, Yozgat 66000, Turkey.
  • Department of Headache, Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 1417653761, Iran.
  • School of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy.

ORCID-Profile: Dilara Onan, Paolo Martelletti

Zitieren

APA

Onan, D., Farham, F., & Martelletti, P. (2024). Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine. Toxins, 16(7), 309. https://doi.org/10.3390/toxins16070309

Vancouver

Onan D, Farham F, Martelletti P. Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine. Toxins. 2024;16(7):309. doi:10.3390/toxins16070309

BibTeX
@article{Onan2024,
  author = {Onan, Dilara and Farham, Fatemeh and Martelletti, Paolo},
  title = {Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine},
  journal = {Toxins},
  year = {2024},
  volume = {16},
  number = {7},
  pages = {309},
  doi = {10.3390/toxins16070309}
}
Kostenlos starten →